Fibronectin polypeptides and methods of use
Described herein are fragments of fibronectin and variants thereof that bind growth factors. Compositions containing such a fragment of fibronectin are therefore useful in sequestering growth factors, and complexes containing both a FN fragment and a bound, active growth factor can be used to deliver growth factors to a patient (e.g., to a wound on the patient's skin).
1. A method of promoting wound healing in a patient, the method comprising administering to the patient a therapeutically effective amount of a pharmaceutical or physiologically acceptable composition comprising a polypeptide, wherein the polypeptide consists of the amino acid sequence QPSHISKYILRWRPK (SEQ ID NO:7).
2. The method of claim 1 , wherein the pharmaceutical or physiologically acceptable composition is formulated for topical administration.
3. The method of claim 1 , wherein the patient is suffering from a laceration, burn, or ulceration of the skin.
4. A method of promoting wound healing in a patient, the method comprising administering to the patient a therapeutically effective amount of a pharmaceutical or physiologically acceptable composition comprising a polypeptide, wherein the polypeptide consists of the amino acid sequence QPSHISKYILRWRPK (SEQ ID NO:7) having two additional cysteine residues, a first cysteine residue at the N-terminus and a second cysteine residue at the C-terminus.
5. The method of claim 4 , wherein the polypeptide is in a cyclic form.
6. The method of claim 4 , wherein the pharmaceutical or physiologically acceptable composition is formulated for topical administration.
7. The method of claim 4 , wherein the patient is suffering from a laceration, burn, or ulceration of the skin.
8. A method of promoting wound healing in a patient, the method comprising administering to the patient a therapeutically effective amount of a pharmaceutical or physiologically acceptable composition comprising a polypeptide, wherein the polypeptide consists of the amino acid sequence QPSHISKYILRWRPK (SEQ ID NO:7) and a heterologous sequence that increases the circulating half-life of the polypeptide.
9. The method of claim 8 , wherein the heterologous sequence that increases the circulating half-life of the polypeptide is an albumin or a portion of an immunoglobulin.
10. The method of claim 9 , wherein the albumin is a human serum albumin or a portion thereof and the portion of an immunoglobulin is the Fc region of an IgG.
11. The method of claim 8 , wherein the pharmaceutical or physiologically acceptable composition is formulated for topical administration.
12. The method of claim 8 , wherein the patient is suffering from a laceration, burn, or ulceration of the skin.